A Consensus Parameter for the Evaluation and Management of Angioedema in the Emergency Department

Overview

Journal Acad Emerg Med

Publisher Wiley

Specialty Emergency Medicine

Date 2014 Apr 16

PMID 24730413

Citations 54

Authors

Joseph J Moellman

Jonathan A Bernstein

Christopher Lindsell

Aleena Banerji

Paula J Busse

Carlos A Camargo Jr

Sean P Collins

Timothy J Craig

William R Lumry

Richard Nowak

Jesse M Pines

Ali S Raja

Marc Riedl

Michael J Ward

Bruce L Zuraw

Deborah Diercks

Brian Hiestand

Ronna L Campbell

Sandra Schneider

Richard Sinert

Affiliations

Soon will be listed here.

Abstract

Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioedema from one another and more specifically differentiate histaminergic-mediated angioedema from bradykinin-mediated angioedema, especially in lieu of the more novel treatments that have recently become available for bradykinin-mediated angioedema. With this background in mind, this consensus parameter for the evaluation and management of angioedema attempts to provide a working framework for emergency physicians (EPs) in approaching the patient with angioedema in terms of diagnosis and management in the ED. This consensus parameter was developed from a collaborative effort among a group of EPs and leading allergists with expertise in angioedema. After rigorous debate, review of the literature, and expert opinion, the following consensus guideline document was created. The document has been endorsed by the American College of Allergy, Asthma & Immunology (ACAAI) and the Society for Academic Emergency Medicine (SAEM).

Citing Articles

Deaths from Angioedema-Anaphylaxis and Covid-19.

Gray A, Ou R, Djabourian R, Augustine J, Sathyavagiswaran L Acad Forensic Pathol. 2025; :19253621251320212.

PMID: 39991143 PMC: 11843567. DOI: 10.1177/19253621251320212.

Valsartan/Sacubitril induced isolated angioedema of uvula: A case report.

Nazzal M, Iter A, Dawabsheh A, Bsharat M Heliyon. 2024; 10(21):e39423.

PMID: 39524712 PMC: 11546446. DOI: 10.1016/j.heliyon.2024.e39423.

Unveiling the Complexities of Hereditary Angioedema.

Tutunaru C, Ica O, Mitroi G, Neagoe C, Mitroi G, Orzan O Biomolecules. 2024; 14(10).

PMID: 39456231 PMC: 11506744. DOI: 10.3390/biom14101298.

Glass Ionomer Cement Induced Angioedema: Seldom Encounter in Prosthodontic Practice-A Case Report.

Taraphdar S, Manna A, Karmakar A, Sarkar A J West Afr Coll Surg. 2024; 14(4):428-431.

PMID: 39309377 PMC: 11412592. DOI: 10.4103/jwas.jwas_157_23.

Angiotensin-Converting Enzyme (ACE) Inhibitor-Induced Angioedema in an African American Male With Coronavirus Disease 2019 (COVID-19).

Bresler R, Whelan J Cureus. 2024; 16(5):e60852.

PMID: 38910667 PMC: 11191406. DOI: 10.7759/cureus.60852.

References

Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H . WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J. 2013; 5(12):182-99. PMC: 3651186. DOI: 10.1097/WOX.0b013e318279affa. View

Wahn V, Aberer W, Eberl W, Fasshauer M, Kuhne T, Kurnik K . Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies. Eur J Pediatr. 2012; 171(9):1339-48. PMC: 3419830. DOI: 10.1007/s00431-012-1726-4. View

Zuraw B, Christiansen S . Pathophysiology of hereditary angioedema. Am J Rhinol Allergy. 2011; 25(6):373-8. DOI: 10.2500/ajra.2011.25.3661. View

Moellman J, Bernstein J . Diagnosis and management of hereditary angioedema: an emergency medicine perspective. J Emerg Med. 2012; 43(2):391-400. DOI: 10.1016/j.jemermed.2011.06.125. View

Bentsianov B, Parhiscar A, Azer M, Har-El G . The role of fiberoptic nasopharyngoscopy in the management of the acute airway in angioneurotic edema. Laryngoscope. 2000; 110(12):2016-9. DOI: 10.1097/00005537-200012000-00007. View

Stojiljkovic L . Renin-angiotensin system inhibitors and angioedema: anesthetic implications. Curr Opin Anaesthesiol. 2012; 25(3):356-62. DOI: 10.1097/ACO.0b013e328352dda5. View

Baeza M, Rodriguez-Marco A, Prieto A, Rodriguez-Sainz C, Zubeldia J, Rubio M . Factor XII gene missense mutation Thr328Lys in an Arab family with hereditary angioedema type III. Allergy. 2011; 66(7):981-2. DOI: 10.1111/j.1398-9995.2011.02562.x. View

Vazquez Nava F, Almeida Arvizu V, Sanchez Nuncio H, Villanueva Carreto M, Guidos Fogelbach G . [Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico]. Rev Alerg Mex. 2005; 51(5):181-8. View

Han E, MacFarlane R, Mulligan A, Scafidi J, Davis 3rd A . Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002; 109(8):1057-63. PMC: 150945. DOI: 10.1172/JCI14211. View

10.

Bork K, Meng G, Staubach P, Hardt J . Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006; 119(3):267-74. DOI: 10.1016/j.amjmed.2005.09.064. View

11.

Zanichelli A, Badini M, Nataloni I, Montano N, Cicardi M . Treatment of acquired angioedema with icatibant: a case report. Intern Emerg Med. 2010; 6(3):279-80. DOI: 10.1007/s11739-010-0431-4. View

12.

Bork K, Barnstedt S, Koch P, Traupe H . Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000; 356(9225):213-7. DOI: 10.1016/S0140-6736(00)02483-1. View

13.

Bork K, Hardt J, Witzke G . Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012; 130(3):692-7. DOI: 10.1016/j.jaci.2012.05.055. View

14.

Miller D, Oliveria S, Berlowitz D, Fincke B, Stang P, Lillienfeld D . Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008; 51(6):1624-30. DOI: 10.1161/HYPERTENSIONAHA.108.110270. View

15.

Bork K . Recurrent angioedema and the threat of asphyxiation. Dtsch Arztebl Int. 2010; 107(23):408-14. PMC: 2893523. DOI: 10.3238/arztebl.2010.0408. View

16.

Al-Khudari S, Loochtan M, Peterson E, Yaremchuk K . Management of angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope. 2011; 121(11):2327-34. DOI: 10.1002/lary.22349. View

17.

Agah R, Bandi V, Guntupalli K . Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med. 1997; 23(7):793-6. DOI: 10.1007/s001340050413. View

18.

Epstein T, Bernstein J . Current and emerging management options for hereditary angioedema in the US. Drugs. 2008; 68(18):2561-73. DOI: 10.2165/0003495-200868180-00003. View

19.

Yamamoto T, Horiuchi T, Miyahara H, Yoshizawa S, Maehara J, Shono E . Hereditary angioedema in Japan: genetic analysis of 13 unrelated cases. Am J Med Sci. 2011; 343(3):210-4. DOI: 10.1097/MAJ.0b013e31822bdb65. View

20.

Frazer-Abel A, Giclas P . Update on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema. Allergy Asthma Proc. 2011; 32 Suppl 1:17-21. DOI: 10.2500/aap.2011.32.3472. View